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Given an appreciable risk of adverse-effects, chronic hepatitis C virus (HCV) patients face a 
dilemma regarding whether to accept or forego a course of therapy that can permanently clear 
their viral infection.  
OBJECTIVE 
To inform this decision point, we explored (via simulation modelling) patient-important benefits 
of treatment-induced viral-clearance according to individualised patient factors. 
DESIGN: 
We created the HCV Individualised Treatment-decision model (the HIT-model) to simulate, on a 
per patient basis, the lifetime course of HCV-related liver disease. 
SETTING: 
The HIT-model is applicable to settings where chronic HCV patients are considered for antiviral 
therapy; by and large secondary referral specialist care centres. 
PARTICIPANTS:  
Hypothetical persons with chronic HCV infection aged 30-60 years with varying degrees of liver 
fibrosis (mild, moderate and severe). 
EXPOSURE: 
The lifetime course of liver disease was simulated, on a per patient basis, according to two 
distinct scenarios: (i) treatment-induced viral-clearance attained, and (ii) treatment-induced viral-
clearance not attained. Then, for each model subject, the course of liver disease under these 
alternative scenarios was compared.  
MAIN OUTCOMES:  
4 
Emphasis was on patient-important outcomes; in particular: (1) Probability of viral-clearance 
conferring additional total life years, and (2) Probability of viral-clearance conferring additional 
life years spent in compensated health states (i.e. the avoidance of liver failure).  
RESULTS: 
The probability of benefiting from treatment-induced viral-clearance varied strikingly. It was 
lowest among patients at 60 years of age with initially mild fibrosis; 1.6% (95% CI: 0.8-2.7) and 
2.9% (95% CI: 1.5-4.7) regarding outcome 1 and 2, respectively. It was highest among patients 
with compensated cirrhosis aged 30 years; 57.9% (95% CI: 46.0-69.0) and 67.1% (95% CI: 54.1-
78.2) regarding outcome 1 and 2, respectively.  
CONCLUSIONS: 
For older patients with less advanced liver fibrosis, viral-clearance is less likely to confer benefit 
when measured in terms of averting liver failure and premature death. These data have important 
implications. Foremost, they will inform the contemporary patient quandary of immediate 
treatment with existing therapies (that have poor adverse-effect profiles) versus deferring until 














Chronic hepatitis C virus (HCV) infection leads to progressively worsening degrees of liver 
fibrosis (i.e. scarring of the liver). Eventually (over a period of many decades), fibrosis can 
become so extensive, that liver function is compromised.
1 
Often, it is only at this point of hepatic 
decompensation that HCV infection becomes evident to the patient. Hereafter, in the absence of a 
liver transplant, long-term prognosis is bleak.
2
 It is this typical sequence of events that has led to 




Chronic HCV infection is treatable. Current treatments regimens (consisting of a 16-48 week 
course of pegylated interferon, ribavirin ± a protease inhibitor in genotype-1 patients) can 
permanently eradicate the infection in 67-75% of persons (based on the sustained viral response 
[SVR] proxy).
5-7 
The number of people treated every year is substantial; approximately 5,000-
6,000, and 60,000-80,000 initiates each year in the UK and US, respectively.
8,9 
However current 
therapies are not a panacea; adverse-effects can be appreciable
10,11
 and sometimes severe.
12-14
 
Moreover, patients failing first generation protease inhibitors can develop resistance to the class.
15
 
Accordingly, before embarking on a course of therapy, the patient (and their clinician) should 
carefully consider the risk-benefit ratio. Particularly given that, de-facto, the majority with 
infection are unlikely to develop overt liver disease, within the course of their lifetime
16,17
 So, to 
assist this patient-decision we simulated the lifetime course of liver disease according to SVR 
status and individualised patient factors. We envisage that these data, in conjunction with 
information regarding: (i)the probability of SVR, (ii)the adverse-effect profile, and (iii)the 
prospect that more tolerable and efficacious therapies will be available in the future
18
, will arm 
patients and clinicians alike, with a more complete picture when considering therapy with current 
(and future
18







To delineate the value of treatment-induced viral clearance, we created the Hepatitis-C 
Individualised Treatment-decision model (the HIT-model). The HIT-model simulates lifetime 
liver disease outcomes for individual model subjects, henceforth from two distinct scenarios: 
(i) SCENARIO-1: Treatment-induced viral-clearance attained - i.e. the patient accepts a 
course of antiviral therapy and attains SVR. 
(ii) SCENARIO-2: Treatment-induced viral-clearance not attained - i.e. the same patient 
alternatively either declines therapy or fails, hence their chronic infection persists 
over their remaining life course. 
For each model subject, we then compared the course of liver disease under scenario-1 versus 
scenario-2.   
 
MODEL OVERVIEW: 
The HIT-model is a markov-chain model that simulates the lifetime course of HCV-related liver 
disease according to viral-clearance status. The model is run as a first order Monte-Carlo 
simulation, otherwise known as a microsimulation.
19,20
 The structure and parameterisation it 
assumes (see Fig-1 and Table-1) is typical of existing HCV simulation models (be they cost-
effectiveness
21-24
 or burden forecasting models
25-27
) and draws on a wide array of empirical 
research data.  
 
As per the schematic in Fig.1, subjects under scenario-2 (persisting chronic HCV infection) face 
progressive hepatic fibrosis, culminating in compensated cirrhosis (i.e. Ishak-6). Probabilities 
used to inform the progression of model subjects through these early stages were derived from a 




same progression rates (based on 12% of persons developing compensated cirrhosis within 20 
years of acquiring infection) have been adopted in hitherto HCV simulation models.
21, 23-24
 Once 
(if at all) subjects reach Ishak-6, they then risk the development of decompensated liver cirrhosis 
and hepatocellular carcinoma (HCC). If either of these two health states are attained, subjects 
may then die a HCV liver-related death (occurring at an annual risk of 43% and 13% from HCC 
and decompensated liver cirrhosis states, respectively
28
), but are also eligible for a liver 
transplantation (occurring according to a 2% annual probability
26
), which can improve long-term 
prognosis (i.e. 14.6% risk of a HCV-related death during the year transplant occurs, but 4.4% for 
every year thereafter
26
). In scenario-1 (attainment of viral-clearance), we assumed subjects with 
mild/moderate fibrosis could not progress to more advanced states of liver disease. In contrast, 
subjects with initial cirrhosis (Ishak-6) could progress to decompensated cirrhosis or HCC health 
states (and downstream states thereafter), but at a reduced rate relative to scenario-2
29
 (see Table-
1).  At every stage of the model (for both scenarios equally), subjects were susceptible to death 
from causes unrelated to HCV infection. Based on empirical data, we assumed these deaths 
occurred at an increased rate relative to the general population.
30-34 
Finally, disease progression 
was simulated in annual cycles, until a maximum age of 90 years.  
 
INDIVIDUALISED PATIENT FACTORS: 
Outcomes were stratified according to individualised patient factors; these being initial fibrosis 
stage (Ishak 0-2, 3-5 and 6) and age (30, 45 and 60 years). Thus in total, disease course was 
simulated separately according to nine distinct patient types (i.e. all possible permutations of 
fibrosis stage and age). 
 
PRIMARY OUTCOMES: 
These reflected: patient-important events (those "perceptible to the patient and of sufficient value 
that changing their frequency would be of value to the patient"
35
); the inceptive rationale for 
8 
therapy (i.e. to prevent HCV-related complications and death
36
); and the chief concerns of 
patients (premature-death and disease progression).
37
 Hence as follows: 
(i) OUTCOME-1: The likelihood of viral-clearance conferring additional years of life 
(ii) OUTCOME-2: The likelihood of viral-clearance conferring additional years of life in 
compensated health states (i.e. the avoidance of liver failure). 
The rationale for outcome-2 is that in compensated disease states, the functioning of the liver 
is (by and large) unimpaired (i.e. by its very definition, the liver is able to compensate for the 
damage incurred). Accordingly, patient preferences for mild, moderate and compensated 
cirrhosis states do not differ.
38,39
   
 
EXPRESSING OUTCOMES THROUGH PROBABILITY DISTRIBUTIONS: 
Regarding outcome-1, we assembled the probability distribution for total life years gained (i.e. all 
life years gained in non-absorbing disease states) through attaining viral-clearance (versus the 
alternative scenario of persisting chronic infection). From the resulting distribution, we draw 
particular attention to the probability of gaining >0 additional life-year(s). Similarly with regards 
to outcome-2, we compiled the probability distribution for life years gained in compensated 
health states, and emphasise the probability of gaining >0 additional year(s). 
 
EXPRESSING OUTCOMES THROUGH THE NUMBER-NEEDED-TO-SVR: 
We determined the number needed to attain SVR in order to prevent one patient dying a 
premature HCV-related death (NNS1); calculated as the reciprocal of the probability of gaining 
>0 additional life-years. Equally, we calculated the number needed to attain SVR in order to avert 
one patient from prematurely developing overt liver disease (NNS2); calculated as the reciprocal 
of the probability of gaining >0 additional years in compensated health states.  
The NNS is a HCV bespoke version of the number needed to treat (NNT). The NNT (referring to 
the number of patients that need to be treated in order to avert one additional adverse outcome) is 
9 
well-regarded among clinicians as a meaningful measure of the effectiveness of a medical 
intervention.
40,41 
Thus, the rationale for additionally framing the benefit of viral-clearance in an 
NNS format is to assist interpretation by clinicians and their patients (the target audience of this 
paper).   
 
UNCERTAINTY DUE TO SAMPLING ERROR: 
To quantify the overall uncertainty in our outcomes attributable to sampling error, we assigned 
probability distributions to model parameters (as specified in Table-1), and sampled randomly 
from these. As is recommended for microsimulation models,
20
 we adopted a stratified sampling 
approach (Latin hypercube) enabling a more efficient coverage of the sampling space than non-
stratified sampling alone (thus permitting fewer replications and a less onerous computational 
intensity). For each set of random parameter draws (1000 performed in total) we ran each type of 
patient through the model 10,000 times (thus equating to 10 million simulations in total for each 




 percentiles) of each outcome 
across these 1,000 parameter draws was used derive a 95% uncertainty interval.  
 
SENSITIVITY ANALYSES: 
We performed three one-way sensitivity analyses (SA) to assess the variability of our outcomes to 
pivotal parameters. As follows: 
1. SA-1: We increased our base case fibrosis progression parameters, pro rata, to reflect 




2. SA-2: We decreased our base case fibrosis parameters, pro rata, to reflect 7% progression 
to cirrhosis at 20 years. The lower 7% progression rate
43
 is appropriate when modelling 
the general infected population
44 









OUTCOMES IN TERMS OF PROBABILITY DISTRIBUTIONS: 
Gains in total life-years (outcome-1) and life-years spent in compensated disease states (outcome-
2) attributable to viral-clearance, exhibited highly skewed distributions (see eFigure 1-2). For 
patients with initially mild or moderate fibrosis these probability distributions bespeak a situation 
where the majority gains minimally, but the minority gains considerably. Gains were more likely 
and more substantial for those treated at advanced fibrosis stages and younger ages. Patients with 
mild fibrosis at age 60 years of age had the lowest probability of benefiting from a SVR; a 1.6% 
(95%CI: 0.8-2.7) and 2.9% (95%CI: 1.5-4.7) chance in relation to outcome-1 and outcome-2, 
respectively (see Table-2). In contrast, patients with compensated cirrhosis at 30 years of age had 
the greatest probability of benefiting from a SVR; a 57.9% (95%CI: 46.0-69.0) and 67.0% 
(95%CI: 54.1-78.2) chance in relation to outcome 1 and 2, respectively. Notwithstanding the 
probability of benefiting from viral-clearance being small (particularly so for patients with mild 
and moderate fibrosis), amongst those who did benefit, the magnitude of this benefit was 
considerable; for example 6.2-14.5, 7.8-19.3, and 9.8-23.7 additional life-years for persons 
initially with mild fibrosis, moderate fibrosis and compensated cirrhosis, respectively. 
 
OUTCOMES IN TERMS OF NUMBER-NEEDED-TO-SVR: 
The number needing to attain SVR in order to avert adverse outcomes was highly heterogeneous 
across individualised patient factors (Table-3). For example, on average, only two patients with 
cirrhosis at 30 years would (on average) need to attain SVR in order to avert one HCV-related 
11 
death. Whereas for mildly fibrotic patient aged 60 years, 65 such patients would need to attain 
SVR in order to avert that same one death. Similarly, on average, only two persons (with cirrhosis 
at 30 years of age) would need to attain SVR in order for one patient to gain at least one 
additional year in a compensated health state. This compares to 35 patients (with mild disease at 
60 years of age) that would need to attain SVR in order to achieve that same effect. 
 
SENSITIVITY ANALYSES: 
The likelihood of benefiting from viral-clearance was increased under SA-1 and SA-3, but 
reduced under SA-2 (see Table-4, and eTables 1-6). Nevertheless, for all SAs, the probability of 
benefiting from viral-clearance (in terms of either outcome 1 or 2) remained ≤20% (or 

















Treating populations with chronic HCV is highly cost-effective
21-24
; nevertheless, for the 
individual patient, there are clearly a range of benefits to be had. At its most extreme, the 
probability that a mildly fibrotic person at 60 years of age will benefit from viral-clearance (in 
terms of clinically apparent outcomes) is just 2-3%, whilst it is 58-67% for a cirrhotic person at 
30 years of age (Table-2).This contrast is tantamount to a clinician needing to clear infection in, 
on average, ~35 times as many persons of the former description (versus persons of the latter) in 
order to avert the same number of HCV-related deaths (Table-3). Variation in the merit of a SVR 
is acknowledged neither in clinical guidelines,
36,46
 nor in information made available to 
patients.
47,48
 With this perspective, the use of current treatment regimens (with poor adverse-
effect profiles
 10-14
) to treat older patients with minimal fibrosis, becomes a moot point and a 
challenging decision for patients and physicians. 
 
The view that, in the absence of treatment, severe liver disease is not an inevitable outcome of 
chronic HCV infection is not new. Seeff and Alter have speculated that two thirds of chronic 
HCV patients will not develop severe liver-related manifestations of infection within their 
lifetimes.
16
 Moreover, Yoshida and colleagues calculated the mean gain in HCC-free survival 
attributable to SVR in Japanese patients according to age and fibrosis stage.
49
 Their findings 
mirror ours. More specifically they too noted: (i)the gain in HCC-free survival varies markedly 
according to age and fibrosis stage, and (ii)older patients with mild fibrosis have less to gain from 
treatment. However, Yoshida's study was based entirely on data from Japanese patients and only 
considered HCC-free survival as an outcome. Further, mean gain in HCC-free survival is a 
somewhat misleading summary measure for the individual patient (i.e. the benefit distributions 




 the literature is bereft of data delineating the benefits of therapy 
according to patient factors. Hence, all in all, we consider this study a valuable contribution to the 
evidence base. 
 
Presently, SVR is labelled a "cure"
48 
(language a patient would generally associate with an 
outcome that restores health). Analogously, pre-treatment discussions (between patient and 
clinician) weigh only the probability of SVR against the risk of adverse-effects.
47
In these ways, 
SVR can be portrayed as an outright benefit in itself. We caution that framing viral-clearance in 
this way (without consideration of age or disease-stage) may misguide patients apropos the value 
of therapy. At the same time, HCV initiatives are increasingly geared towards widening access to 
treatment. A simple utilitarian logic underpins this strategy: The more persons treated, the more 
cases of end-stage-liver-disease, in time, will be averted. Screening US baby boomers (persons 
born between 1945 and 1965) for HCV infection (with a view to treating those that screen 
positive) is a case-in-point.
45 
This initiative will identify ~1.6 million patients with chronic 
infection, here-to-fore unaware of their condition. It is estimated that of these 1.6 million, more 
than 50% will be aged 45 years+ with mild fibrosis, or aged 60 yrs+ with moderate fibrosis
50
; in 
other words, patient-groups that gain less from a SVR (assuming SVR is attained at all). Thus, on 
one hand, at the population level, birth-cohort screening will indeed avert a considerable number 
of end-stage liver disease cases over the years to come. All the same, from the perspective of any 
one individual patient, the likelihood of benefit may not always be sufficient to offset the adverse-
effects of therapy. Ultimately, it is for the patient and their clinician (not the authors of this paper) 
to decide what is, and is not, an attractive risk-benefit ratio. However, it is for the medical-
researcher to arm them with an objective assimilation of the data. Accordingly, the data presented 
herein have important potential; particularly to inform the treatment decisions of individuals 
identified with chronic HCV infection via US birth cohort screening. 
 
14 
Hitherto HCV simulation models are pitched at policy makers; insofar as they focus on broad 
population-level outcomes, far-removed from the individual-level decision-to-treat
21-27 
Our focus 
on addressing the questions that matter most to patients, in an intuitive way (in effect advocating 
a new patient-centred modelling approach), is the greatest strength of this paper. Various 
impediments hinder primary research studies, in their own right, from addressing these issues. In 
particular, (i)initial infection is asymptomatic (so inception cohorts are rare), (ii)liver damage 
thereafter occurs gradually over a course of decades (rendering long-term follow-up difficult), 
(iii)antiviral therapy post-diagnosis is ubiquitous (thus adulterating the picture going forward), 
and (iv)the gold standard means of assessing liver stage (a liver biopsy) is an invasive procedure 
and performed sparingly.
17
 The simulation approach adopted here, draws on primary research 
data to generate the most plausible inference to the question-at-hand. However, results will rest 
on certain assumptions. In particular, the HIT-model assumes a constant (linear) course of 
fibrosis progression over the lifetime of the patient (as per hitherto HCV models
21,23,24,26
, and as is 
consistent with current observational data
51
). However, there is uncertainty in this assumption; 
fibrotic accretion may accelerate with time (particularly after 30 years of infection; a follow-up 
duration few observational studies exceed) and in this eventuality, our findings may be affected. 
These uncertainties (not reflected in our confidence intervals) should be made clear. Secondly 
despite stratifying by age and disease-stage, patients and clinicians may argue that the HIT-model 
still remains too broad-brush. In particular, alcohol (which contributes to disease progression 
enormously
52
) is ignored. Future research should better characterise the course of disease 
progression in the absence of heavy alcohol use and incorporate these findings into a patient-
centred modelling approach. Similarly, differences in disease progression, by gender, should also 
be considered. Thirdly, the HIT-model frames the benefit of SVR in terms of averting liver 
failure and premature death; sequelae that concern HCV patients most.
37 
However, these 
outcomes may not capture the totality of HCV-induced adversities, and as such may understate 
the benefits of therapy. In particular: 
15 
(a) Compensated cirrhosis is frequently asymptomatic, but not always53; some patients present 
with non-specific symptoms (dyspepsia, asthenia. upper abdominal discomfort, etc). The 
precise symptomatic-asymptomatic ratio is undetermined. Fattovich et al report that among 
patients referred to tertiary clinics following diagnosis of compensated cirrhosis, 43% 
demonstrated such symptoms, and 57% did not (although, N.B, a referral bias in favour of 
symptomatic patients is clearly likely to operate in this type of cohort).
28 
;  
(b) HCV infection can predispose one to various non-liver-related conditions 
(cryoglobulinaemia, lichen planus, vitiligo, porphyria cutanea tarda and B-cell 
lymphomas
54,55
) which are not considered in our model (although, barring cryoglobulinemia, 
these conditions are relatively infrequent).  
(c) Our simulation model does not include the possibility that SVR benefits the patient vis-à-vis 
non-liver-related mortality.
 
An association between chronic HCV infection per se and 
increased non-liver mortality is equivocal and not supported by many key studies.
56-59
 
Ongoing scrutiny however, particularly with regard to vascular disease
60
, is required.  
 
There are important implications to these data. In the short-term, this work will inform the 
contemporary patient dilemma of immediate treatment with existing therapies (that have poor 
adverse-effect profiles) versus awaiting interferon-free regimens that promise higher SVR rates 
with better tolerability.
17
 Longer-term, it urges that broadened access to therapy be twinned with 








Authors contributions: Hamish Innes and Prof. Sharon Hutchinson had full access to all of the 
data generated by this model and take full responsibility for the integrity and accuracy of the 
analysis. 
Study concept and design: Innes and Hutchinson. 
Analysis and interpretation of data: Innes, Dusheiko, Goldberg, Hayes, Mills, Dillon, Aspinall, 
Barclay and Hutchinson 
Drafting of the manuscript: Innes, Dusheiko, Goldberg, Hayes, Mills, Dillon, Aspinall, Barclay 
and Hutchinson 
Financial disclosures: G Dusheiko has received research and grant support from, has acted as a 
clinical investigator or chief investigator and has served on advisory boards  for Gilead Sciences, 
Vertex, Abbott, Boehringer Ingelheim, Bristol Myers, Glaxo Smith Kline, Pharmasett, Merck, 
Janssen. 
Funding/Support: This work was supported through funding from the Scottish government. 




(1) Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. 
Hepatology. 2002;36(5 Suppl 1):S47-56 
(2) D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of 
survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217-231. 
(3) Edlin BR. Perspective: test and treat this silent killer. Nature. 2011;474(7350):S18-19. 
(4) Detonating a viral time bomb--the hepatitis C pandemic. Lancet. 2013;381(9862):178. 
17 
(5) Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV 
genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206.  
(6) Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated 
chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416.  
(7) Innes HA, Hutchinson SJ, Allen S , et al. Ranking predictors of a sustained viral response 
for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in 
Scotland. Eur J Gastroenterol Hepatol. 2012;24(6):646-655.  
(8) Health Protection Agency. Hepatitis C in the UK. 2012. 
www.hpa.org.uk/Publications/InfectiousDiseases/BloodBorneInfections/HepatitisCInThe
UK/.  Accessed May 2013. 
(9) Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for 
hepatitis C in the United States. Hepatology. 2009;50(6):1750-1755.  
(10) Manos MM, Ho CK, Murphy RC, Shvachko VA. Physical, social, and 
psychological consequences of treatment for hepatitis C : a community-based evaluation 
of patient-reported outcomes. Patient. 2013; 6(1):23-34.  
(11) Fried et al. Side effects of hepatitis c and their management  Hepatology. 
2002;36(5 Suppl 1):S237-S244. 
(12) US Food and Drug Administration. Drug safety communication. 
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedical
Products/ucm332860.htm   . Accessed January 2013 
(13) Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced 
patients with HCV-cirrhosis in a multicentre cohort of the french early access programme 
(anrs c020-cupic)-nct01514890. [published online ahead of print 13
th
 May 2013] J 
Hepatol. 2013. doi: 10.1016/j.jhep.2013.04.035. 
18 
(14) Maasoumy B, Port K, Markova AA, et al. Eligibility and safety of triple therapy 
for hepatitis C: lessons learned from the first experience in a real world setting. PLoS 
One. 2013;8(2):e55285.  
(15) Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus 
infection therapy. J Infect Dis. 2013;207 Suppl 1:S33-39. 
(16) Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus 
infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20(1):17-35.  
(17) Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 
1):S35-46 
(18) Dore GJ. The changing therapeutic landscape for hepatitis C. Med J Aust. 
2012;196(10):629-632. 
(19)  Wever EM, Hugosson J, Heijnsdijk EA, Bangma CH, Draisma G, de Koning HJ. 
To be screened or not to be screened? Modeling the consequences of PSA screening for 
the individual. Br J Cancer. 2012;107(5):778-784.  
(20) Sharif B, Kopec J, Wong H, Fines P, Sayre E, Liu R, et a;. Uncertainty analysis 
in population-based disease microsimulation models. Epidemiology Research 
International. vol. 2012, Article ID 610405, 14 pages, 2012. doi:10.1155/2012/610405 
(21) Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et 
al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user 
populations. Hepatology. 2012;55(1):49-57.  
(22) Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW , et al. 
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary 
care settings. Ann Intern Med. 2012;156(4):263-270.  
(23) Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. 
Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for 
histologically mild chronic hepatitis C. Gut. 2006;55(9):1332-1338.  
19 
(24) Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral 
therapy for mild chronic hepatitis C: randomised controlled trial and economic 
evaluation. Health Technol Assess 2006;10(21):1-113, iii.  
(25) Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C 
virus (HCV)-infected persons in the United States: a multiple cohort model of HCV 
prevalence and disease progression. Gastroenterology. 2010;138(2):513-521, 521 e511-
516.  
(26) Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease 
burden of hepatitis C among injection drug users in Scotland. Hepatology. 
2005;42(3):711-723.  
(27) Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. 
Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic 
chronic hepatitis C in the United States. Dig Liver Dis. 2011; 43(1):66-72.  
(28) Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens 
F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-
up study of 384 patients. Gastroenterology. 1997;112(2):463-472. 
(29) Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative 
effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic 
review. Ann Intern Med.2013;158(2):114-123.  
(30) Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after 
diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. 
Lancet. 2006;368(9539):938-945.  
(31) Duberg AS, Torner A, Davidsdottir L, Aleman S, Blaxhult A, Svensson A, et al. 
Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide 
community-based register study. J Viral Hepat. 2008;15(7):538-550.  
20 
(32) El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-
related mortality among HCV-infected individuals in the general US population. Clin 
Infect Dis.2011;53(2):150-157.  
(33) McDonald SA, Hutchinson SJ, Bird SM, Mills PR, Dillon J, Bloor M, et al. A 
population-based record linkage study of mortality in hepatitis C-diagnosed persons with 
or without HIV coinfection in Scotland. Stat Methods Med Res. 2009;18(3):271-283.  
(34) Prasad L, Spicher VM, Negro F, Rickenbach M, Zwahlen M. Little evidence that 
hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess 
alcohol intake: the Swiss Hepatitis C Cohort Study. J Viral Hepat. 2009;16(9):644-649.  
(35) Crowther MA. Introduction to surrogates and evidence-based mini-reviews. 
Hematology Am Soc Hematol Educ Program. 2009:15-16.  
(36) Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and 
treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.  
(37) Minuk GY, Gutkin A, Wong SG, Kaita KD. Patient concerns regarding chronic 
hepatitis C infections. J Viral Hepat. 2005;12(1):51-57. 
(38) Hsu PC, Krajden M, Yoshida EM, Anderson FH, Tomlinson GA, Krahn MD. 
Does cirrhosis affect quality of life in hepatitis C virus-infected patients? Liver Int. 
2009;29(3):449-458. 
(39) Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, 
Krahn M. Health-state utilities and quality of life in hepatitis C patients. Am J 
Gastroenterol 2003;98(3):630-638. 
(40) Laupacis A, Sackett DL, Robert RS. An assessment of clinically useful 
measurements of the consequences of treatment. N Eng J Med. 1988; 318(26):1728-1733 
(41) Chatellier G, Zapletal E, Lemaitre D, et ak. The number needed to treat: a 
clinically useful nomogram in its proper context. BMJ. 1996; 312(7028):426-429.  
21 
(42) Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis 
progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-
regression. Hepatology. 2008;48(2):418-431. 
(43) Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, 
Marinos G, et al. Estimating progression to cirrhosis in chronic hepatitis C virus 
infection. Hepatology. 2001;34(4 Pt 1):809-816. 
(44) Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common 
outcome for people with chronic hepatitis C? J Gastroenterol Hepatol, 2002;17(4):423-
430. 
(45) Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. 
Hepatitis C virus testing of persons born during 1945-1965: recommendations from the 
Centers for Disease Control and Prevention. Ann Intern Med;157(11):817-822.  
(46) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J 
Hepatol;55:245-264.  
(47) Brau N. Evaluation of the hepatitis C virus-infected patient: the initial encounter. 
Clin Infect Dis. 2013;56(6):853-860.  
(48) NHS choices website. Hepatitis C- Treatment. 
http://www.nhs.uk/Conditions/Hepatitis-C/Pages/Treatment.aspx  . Accessed March 
2013: 
(49) Yoshida et al. Benefit of interferon therapy in hepatocellular carcinoma 
prevention for individual patients with chronic hepatitis c. Gut. 2004;53(3):425-430. 
(50) McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, et 
al. Economic model of a birth cohort screening program for hepatitis C virus. 
Hepatology. 2012;55(5):1344-1355.  
22 
(51) Kim WR, Poterucha JJ, Benson JT, Therneau TM. The impact of competing risks 
on the observed rate of chronic hepatitis C progression. Gastroenterology. 
2004;127(3):749-755.  
(52) Innes HA, Hutchinson SJ, Barclay S, Cadzow E, Dillon JF, Fraser A, et al. 
Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C 
virus patients: Implications for treatment cost-effectiveness. Hepatology. 2011;57(2):451-
460.  
(53) Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-851. 
(54) El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of 
hepatitis C among United States male veterans. Hepatology. 2002;36(6):1439-1445. 
(55) Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma 
and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 
2007;297(18):2010-7.  
(56) Uto H, Stuver SO, Hayashi K, et al. Increased rate of death related to presence of 
viremia among hepatitis C virus antibody-positive subjects in a community-based cohort 
study. Hepatology. 2009;50(2):393-399.  
(57) Harris HE, Ramsay ME, Andrews NJ. Survival of a national cohort of hepatitis C 
virus infected patients, 16 years after exposure. Epidemiol Infect. 2006;134(3):472-477. 
(58) Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after 
transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood 
Institute Study Group. N Engl J Med. 1992;327(27):1906-1911.  
(59) Kielland KB, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related 
mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J 
Hepatol. 2013;58(1):31-37.  
(60) Petta S, Torres D, Fazio G, et al. Carotid atherosclerosis and chronic hepatitis C: 
a prospective study of risk associations. Hepatology. 2012. 55(5):1317-1323.  
23 
(61) Life Tables for Great Britain, 2008-2010.  





Fig.1: Chronic HCV natural history schematic assumed in the Hepatitis-C Individual-based 
Treatment-decision model
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Table-1: Parameters incorporated into the HIT-model 
       
Health state transition [scenario(s) 
applicable to] 
  Mean annual 
probability of 
transition 
Data source(s) Sampling distribution 2.5-97.5 
percentiles 
 
Pre-decompensated health states       
Mild fibrosis to Moderate fibrosis [2]  2.5%* Wright et al 24 Beta (38.06, 1484.38) 1.8-3.3  
Mild fibrosis to Moderate fibrosis [1]  0.0% † § §  
Moderate fibrosis to Cirrhosis [2]  3.7%¶ Wright et al 24 Beta (26.87, 699.30) 2.5-5.2  
Moderate fibrosis to Cirrhosis [1]  0.0% † § §  
Compensated cirrhosis to decompensated 
cirrhosis [2] 
 3.9% Fattovich et al 28 Beta (14.58, 359.21) 2.2-6.1 
 
Compensated cirrhosis to decompensated 
cirrhosis [1] 
 0.43% Fattovich et al,27 and 
Chou et al 29 ** 
Beta (14.58, 359.21) & 
Uniform (0, 0.21)  
0.0-1.0 
 
Compensated cirrhosis to liver cancer [2]  1.4% Fattovich et al 28 Beta (1.92, 135.12) 0.5-2.8  
Compensated cirrhosis to liver cancer [1]  0.38% Fattovich et al,28 and 
Chou et al 29†† 
Beta (1.92, 135.12) & 
Uniform(0.18, 0.46)  
0.1-1.0 
 
Post-decompensated health states       
Decompensated cirrhosis to liver cancer 
[1&2] 
 1.4% Fattovich et al 28 Beta (5.35, 377.09) 0.5-2.8 
 
Decompensated cirrhosis to liver related 
death [1&2] 
 13.0% Fattovich et al 28 Beta (146.9, 983.1) 11.1-15.0 
 
Decompensated cirrhosis/HCC to liver 
transplant [1&2] 
 2.0% Hutchinson et al 26 Beta (10.18, 498.71) 1.0-3.4 
 
HCC to death [1&2]  43.0% Fattovich et al 28 Beta (116.67, 154.66) 37.2-48.9  
Liver transplant death in first year  [1&2]  14.6% Hutchinson et al 26 Normal (14.6, 1.81) 11.1-18.1  
Liver transplant survival post year 2+ 
[1&2] 
 4.4% Hutchinson et al 26 Normal (4.4, 0.46) 3.5-5.3 
 
non-HCV related mortality       
Age specific probability of non-HCV 
related mortality for UK general 
population [1&2] 
 E.g. from 0.06% (aged 
30-39yrs) to 7.8% 
(aged 80+ yrs)  
UK all-cause mortality 




Factor increase (relative to general 
population) assumed for HCV persons 
30-39 yrs [1&2] 
 7.7 §§ McDonald et al 33 Normal (7.66, 0.60) 6.49-8.85 
 
Factor increase (relative to general 
population) assumed for HCV persons 
40-49 yrs [1&2] 
 4.9 §§ McDonald et al 33 Normal (4.90, 0.58) 3.8-6.0 
 
Factor increase (relative to general 
population) assumed for HCV persons 
50+ yrs [1&2] 
  1.7 §§ McDonald et al 33 Normal (1.67, 0.18) 
1.3-2.0  
*Modified to be 3% and 1.8% for sensitivity analysis 1 and 2, respectively    
†  Assumed 0% is based on a conservative assumption in the absence of robust empirical data   
§ Parameter not varied       
¶ Modified to be 2.6% and 4.4% for sensitivity analysis 1 and 2, respectively    
** Systematic review by Chou et al 29 describes a 79-100% factor reduction in the annual risk of decompensated cirrhosis post SVR   
† † Systematic review by Chou et al 29 describes a 54-82% factor reduction in the annual risk of liver cancer with SVR   
§§ Modified to 1 for sensitivity analysis 3      
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Table-2: Impact of treatment-induced viral clearance in terms of: (i) total life years gained, and (ii) years gained in compensated disease states, according to 
individual patient factors 
         
Cohort (i) Total life years gained  (ii) Years gained in compensated disease states 




% Probability of gaining 
>0 years  (95% interval)  
Mean years gained, 
among persons gaining 
>0 years (95% interval) 
  Distribution: 
Median (IQR) 
% Probability of 
gaining >0 years  
(95% interval)  
Mean years gained, 
among persons gaining 
>0 years (95% 
interval) 
          
Mild (Ishak 0-2) 30 0 (0-0) 13.6 (8.5-19.4) 14.5 (13.5-15.6)  0 (0-0) 17.9 (11.5-25.1) 16.0 (14.9-17.2) 
45 0 (0-0) 6.3 (3.5-9.6) 10.0 (9.1-10.8)  0 (0-0) 9.4 (5.4-14.1) 11.1 (10.2-12.0) 
60 0 (0-0) 1.6 (0.8-2.7) 6.2 (5.4-7.1)  0 (0-0) 2.9 (1.5-4.7) 7.0 (6.3-7.7) 
          
Moderate (Ishak 3-5) 30 0 (0-14) 40.0 (27.9-51.7) 19.3 (17.7-20.9)  0 (0-20) 48.1 (34.4-60.7) 21.6 (19.8-23.4) 
45 0 (0-1) 26.0 (16.7-36.1) 12.9 (11.9-14.0)  0 (0-7) 34.5 (22.9-46.6) 14.7 (13.5-15.9) 
60 0 (0-0) 10.6 (6.2-16.2) 7.8 (7.1-8.4)  0 (0-0) 17.1 (10.4-24.9) 8.9 (8.2-9.6) 
          
Compensated cirrhosis (Ishak 
6) 
30 7 (0-26) 57.9 (46.0-69.0) 23.7 (21.8-25.8)  13 (0-32) 67.1 (54.1-78.2) 25.7 (23.2-28.7) 
45 0 (0-15) 49.3 (36.7-60.9) 16.4 (15.2-17.8)  7 (0-21) 60.6 (46.1-73.2) 18.5 (16.8-20.3) 













Table-3: Number needed to attain sustained viral response in order, on average: (i) to avert one patient from a dying a HCV-related 
death (NNS1), and (ii) for one patient to spend at least one additional year in a compensated health state (NNS2), according to initial 
fibrosis stage and age. 
       
Initial fibrosis stage Initial age 
(years) 
NNS1 (95% 
interval)* to 1 
decimal place 
NNS2 (95% 
interval)* to 1 
decimal place 
     
Mild (Ishak 0-2) 30 7.4 (5.1-11.7) 5.6 (4.0-8.7) 
45 16.1 (10.4-28.4) 10.8 (7.1-18.5) 
60 64.9 (36.8-125.0) 35.0 (21.1-64.5) 
     
Moderate (Ishak 3-5) 30 2.5 (1.9-3.6) 2.1 (1.6-2.9) 
45 3.9 (2.8-6.0) 2.9 (2.1-4.3) 
60 9.5 (6.1.-16.2) 5.9 (4.0-9.6) 
     
Compensated cirrhosis 
(Ishak 6) 
30 1.7 (1.4-2.2) 1.5 (1.3-1.8) 
45 2.0 (1.6-2.7) 1.6 (1.4-2.2) 
60 3.2 (2.4-4.6) 2.2 (1.7-3.1) 














Table-4: Probability that treatment-induced viral clearance confers: (i) additional life year(s), and (ii) additional year(s) spent in compensated health states, 
according to sensitivity analyses (SA) 1-3.  
         
Cohort (i) Probability of gaining >0 additional life years (95% 
interval) 
 (ii) Probability of gaining >0 addition years in 
compensated disease states (95% interval) 
Initial fibrosis stage Initial 
age 
(years) 
SA 1 - 16% 
cirrhosis 
progression at 20 
years 
SA 2 - 7% 
cirrhosis 
progression at 20 
years 





SA 1 - 16% 
cirrhosis 
progression at 20 
years 
SA 2 - 7% 
cirrhosis 
progression at 20 
years 




          
Mild (Ishak 0-2) 30 17.4 (11.5-24.1) 8.4 (4.3-13.9) 18.8 (12.0-26.2)  22.7 (15.4-30.5) 11.2 (6.0-18.0) 24.1 (15.9-33.1) 
45 8.4 (5.0-12.4) 3.7 (1.7-6.6) 8.8 (5.1-13.0)  12.3 (7.6-17.7) 5.6 (2.7-9.6) 12.5 (7.6-18.1) 
60 2.2 (1.1-3.5) 0.9 (0.4-1.8) 2.5 (1.4-4.0)  4.0 (2.2-6.2) 1.7 (0.7-3.2) 4.4 (2.5-6.8) 
          
Moderate (Ishak 3-5) 30 44.1 (32.4-55.2) 32.6 (20.1-45.7) 50.4 (36.2-63.7)  52.6 (39.8-64.3) 39.6 (24.9-54.3) 58.9 (43.5-72.3) 
45 29.3 (19.6-39.4) 20.5 (11.6-30.8) 32.5 (21.5-44.0)  38.6 (27.0-50.4) 27.4 (16.0-40.3) 41.5 (28.6-54.4) 
60 12.3 (7.1-18.2) 8.1 (4.1-13.3) 14.8 (9.0-21.7)  19.6 (12.4-27.6) 13.2 (6.9-21.3) 22.3 (13.9-31.4) 
          
Compensated 
cirrhosis (Ishak 6) 
30 NA NA 66.7 (54.2-78.2)  NA NA 74.5 (61.3-85.5) 
45 NA NA 55.6 (42.5-67.8)  NA NA 66.2 (51.8-78.5) 
60 NA NA 38.1 (27.1-49.3)   NA NA 51.5 (37.4-64.9) 
 
 
 
